UNITED THERAPEUTICS Corp
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $525.36 ($512.50–$532.39, $4.99M total) across 18 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.05 ($512.92–$522.40, $4.29M total) across 8 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $518.74 ($502.29–$524.59, $4.93M total) across 16 trades on 2026-08-05 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 8 news stories mentioning UTHR (UNITED THERAPEUTICS Corp). Coverage has skewed bullish: 3 bullish, 5 neutral, and 0 bearish.
Recent UTHR coverage spans earnings and insider activity.
In the last 30 days, UTHR insiders filed 235 SEC Form 4 transactions — no purchases and 235 sales ($114.5M). The most active reporter was ROTHBLATT MARTINE A, Chairperson & CEO, with 218 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is a routine, pre-arranged insider sale disclosure; it may slightly affect sentiment but is not a fundamental change by itself.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, which is typically lower-signal than discretionary selling.
This is a disclosed insider sale under a pre-arranged 10b5-1 plan, which typically has limited signaling value but can still affect near-term sentiment.
This is a disclosed insider sale, not a fundamental update, but it can still affect near-term sentiment and positioning.
Lower Q2 revenue but higher net income and EPS suggests margin or mix improvement, which can support near-term sentiment despite top-line softness.
alphai scores every news story that mentions UTHR with an AI model for sentiment and relevance, and aggregates insider trades from UNITED THERAPEUTICS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $525.36 ($512.50–$532.39, $4.99M total) across 18 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readMAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.05 ($512.92–$522.40, $4.29M total) across 8 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $518.74 ($502.29–$524.59, $4.93M total) across 16 trades on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.09 ($512.49–$520.49, $4.91M total) across 9 trades on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readUnited Therapeutics Corporation reported Q2 2026 sales of $783.3M versus $798.6M a year earlier. Net income was $333.0M versus $309.5M. Basic EPS from continuing ops was $7.82 versus $6.86, and diluted EPS was $7.27 versus $6.41. For six months, sales were $1,564.8M versus $1,593.0M; net income $607.9M versus $631.7M.
2 min readUnited Therapeutics reported second-quarter results for the period ended June 30, 2026, with net income rising while revenue fell, according to the company’s earnings release. The article also notes the stock’s recent performance and includes third-party “Trader” and “Investor” composite ratings based on valuation, EPS revisions, and visibility metrics.
2 min readUnited Therapeutics (NASDAQ: UTHR) reported Q2 CY2026 revenue of $783.3 million, down 1.9% year over year but 2.3% above Wall Street estimates, according to the company. GAAP EPS was $7.27, up from $6.41 and 5.9% above consensus. Analysts expect revenue to decline 20.9% over the next 12 months.
6 min readUnited Therapeutics (UTHR) reported Q2 2026 earnings of $7.27 per share, above the $6.97 estimate. Revenue was $783.3 million, below the $821.8 million estimate. The article also cites insider sales totaling 1,373 trades over six months, and notes a median analyst price target of $660.
4 min readUnited Therapeutics (UTHR) reported Q2 net income of $333 million, or $7.27 per share, which beat Wall Street’s $6.82 estimate (Zacks). Revenue was $783.3 million, below the expected $803.5 million (Zacks).
2 min readUnited Therapeutics (Nasdaq: UTHR) reported Q2 2026 results for the quarter ended June 30, 2026. Total revenues fell 2% year over year to $783.3 million. Net income rose 8% to $333.0 million, with diluted EPS up to $7.27. The company also outlined a $2.0 billion share buyback plan and discussed regulatory submissions for ralinepag and Tyvaso.
7 min read
